References
- Bergmann L., Mitrou P. S., Demmer‐Dieckmann M., et al. Impaired T‐ and B‐cell functions in patients with Hodgkin's disease. Reduced mitogenic responsibility and IL‐2 production is not caused by defective CD4+‐cells. Cancer Immunology, Immunotherapy; 1987; 25: 59–64
- Bjorkholm M., Wedelin C., Holm G., Ogenstad S., Johansson B., Mellstedt H. Immune status of untreated patients with Hodgkin's disease and prognosis. Cancer Treatment Reports 1982; 66: 701–9
- Griesinger F., Bergmann L., Barot‐Ciorbaru R., Mitrou P. S. Intrinsic B lymphocyte defect in untreated patients with Hodgkin's disease. Cancer Immunology Immunotherapy 1990; 32: 256–60
- Cimino G., Lo Coco F., Cartoni C., Gallerano T., Luciana M., Lopez Manuela, De Rossi G. Immune‐deficiency in Hodgkin's disease (HD): a study of patients and healthy relatives in families with multiple cases. European Journal of Cancer & Clinical Oncology 1988; 24: 1595–601
- Clerici M., Ferrario E., Trabattoni D., Viviani S., Bonfanti V., Venzon D. J., Clerici E., Shearer G. M., Villa M. L. Multiple defects of T helper cell function in newly diagnosed patients with Hodgkin's disease. European Journal of Cancer 1994; 30A: 1464–70
- De Angelis P., Kimmel M., Lacher M., Flippa D., Melamed M. R. T‐cell subsets in peripheral blood of patients with newly diagnosed and posttreatment Hodgkin's and non‐Hodgkin's lymphomas. Analysis by monoclonal antibody staining and flow cytometry. Analytical & Quantitative Cytology & Histology 1988; 10: 235–42
- Dorreen M. S., Habeshaw J. A., Wrigley P. F., Lister R. A. Distribution of T‐lymphocyte subsets in Hodgkin's disease characterized by monoclonal antibodies. British Journal of Cancel 1982; 45: 491–9
- Tullgren O., Grimfors G., Holm G., Johansson B., Sved‐myr E., Wedelin C., Mellstedt H., Merk K., Bjorkholm M. Lymphocyte abnormalities predicting a poor prognosis in Hodgkin's disease. A long‐term follow‐up. Cancec 1991; 68: 768–75
- Straus D. J., Gaynor J. J., Myers J., Merke D. P., Caravelli J., Chapman D., Yahalom J., Clarkson B. D. Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially noncross‐resistant chemotherapy and intermediate‐dose radiation therapy. J Clin Oncol 1990; 8: 1173–86
- Proctor S. J., Taylor P., Donnan P., Boys R., Lennard A., Prescott R. J. A numerical prognostic index for clinical use in identification of poor‐risk patients with Hodgkin's disease at diagnosis. Scotland and Newcastle Lymphoma Group (SNLG) Therapy Working Party. European Journal of Cancer 1991; 27: 624–9
- Hasenclever D., Diehl V. A prognostic score to predict tumor control in advanced Hodgkin's disease. Proceedings of the XIV meeting of the International Society of Haematology. 1994; S‐014, abstract
- A predictive model for aggressive non‐Hodgkin's lymphoma The International Non‐Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987–94
- Haluska F. G., Brufsky A. M., Canellos G. P. The cellular biology of the Reed‐Stemberg cell. Blood 1994; 84: 1005–19
- Hsu S. M., Hsu P. L. The nature of Reed‐Stemberg cells: phenotype, genotype, and other properties. Crit Rev Oncog 1994; 5: 213–45
- Gruss H. J., Brach M. A., Drexler H. G., Bonifer R., Mer‐telsmann R. H., Herrmann E. Expression Of Cytokine Genes, Cytokine Receptor Genes, and Transcription Factors In Cultured Hodgkin and Reed‐Stemberg Cells. Cancer Research 1992; 52: 3353–60